Associated Behavioral Health Care, a treatment provider offering chemical dependency and mental health services throughout the Puget Sound region, announced today that its Bellevue and Kent facilities now offer transcranial magnetic stimulation (TMS) for the treatment of Major Depressive Disorder (MDD) — making it the first and only provider of TMS in Southeast King County, where mental health services are in demand. Associated Behavioral Health Care is currently offering same-day TMS assessments at all four of its facilities located in King County.
What began as a drug and alcohol education and service facility in 1995, Associated Behavioral Health Care has since evolved into a full-service behavioral health provider.
The most recent addition to its roster of mental health services is NeuroStar Advanced Therapy TMS, which uses magnetic pulses to awaken areas of the brain that are underactive in depression. NeuroStar Advanced Therapy offers doctors real-time feedback and delivers enhanced care with its precise and accurate targeting, providing reliable and consistent treatment. Associated Behavioral Health Care’s Bellevue and Kent locations both currently have growing waiting lists of patients interested in the proven, non-drug treatment option.
The King County Department of Community and Human Services reports one in five area adults has received a diagnosis of depression in their lives. To fill the void for non-invasive depression treatments in the area, Associated Behavioral Health Care plans to offer TMS therapy at all four of its facilities, located in Bellevue, Kent, North Seattle and West Seattle, before the close of 2018, if not sooner. The provider expects to treat 3,000 patients per month — making it the largest provider of TMS in the area. Associated Behavioral Health Care has been conducting grassroots outreach to area healthcare professionals, such as primary care physicians, nurse practitioners, counselors and local health groups to spread awareness of NeuroStar Advanced Therapy TMS as a proven breakthrough treatment that has helped more than 50,000 people find relief from their depression — especially when antidepressants are not working.
“When I joined the practice last year, my top priority was to bring TMS to the area and educate local health practitioners on its effectiveness in treating depression and how it is different from electroconvulsive therapy, as they are often on the front lines of identifying people who are struggling with mental illness,” said Dr. Kalyan Dandala, Chief Medical Officer and Medical Director of Associated Behavioral Health Care. “Since we began offering NeuroStar Advanced Therapy, the demand for this remarkable treatment option has grown tremendously and we quickly learned we would need to expand to our other locations to meet the needs of Puget Sound residents suffering from depression.”
Since receiving FDA clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar Advanced Therapy has become a game-changer in the treatment of depression and offers hope to the 4.5 million people in the U.S. treated for depression who do not benefit from antidepressant medication. With widespread insurance coverage by most commercial and government health plans, including Medicare and Tricare, the non-drug therapy is available by prescription and typically administered daily in a doctor’s office for four to six weeks, with treatment sessions performed in under 19 minutes*. Unlike electroconvulsive therapy (ECT), NeuroStar Advanced Therapy is non-invasive, allows patients to resume daily activities immediately following treatment sessions and is free from side effects often associated with ECT and antidepressants, such as memory loss, fatigue and drowsiness.. In an open-label clinical trial, 58% of patients significantly responded to treatment, and 37% achieved complete remission of their depression symptoms with NeuroStar Advanced Therapy.
“We are incredibly proud to be the only provider in the area offering NeuroStar Advanced Therapy,” Dr. Dandala added. “With this treatment, I have confidence and comfort as I treat my patients because I know it allows for the right treatment dose to be delivered to the right location every time, giving my patients the best possible chance for long-term remission.”
In celebration of its new treatment offering, Associated Behavioral Health Care will host an educational open house event on Thursday, February 22 from 5 – 8 p.m. at its Bellevue facility located at 1800 112th Avenue. Associated Behavioral Health Care is open Monday through Friday from 9 a.m. – 6 p.m. To learn more and schedule an appointment, visit www.ABHC.com.
About Associated Behavioral Health Care
Associated Behavioral Health Care is a treatment provider offering chemical dependency and mental health services, including drug testing, assessments, DUI evaluations, classes (ADIS), and treatments, including transcranial magnetic stimulation, group and individual counseling, psychotherapy and more. With a network of four treatment centers throughout the state of Washington in North Seattle, West Seattle, Bellevue and Kent, Associated Behavioral Health Care encounters approximately 3,000 patients throughout the King County area per month.
About NeuroStar Advanced Therapy
NeuroStar Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. It is backed by the largest clinical data set for Major Depressive Disorder (MDD) of any TMS device. NeuroStar Advanced Therapy is the #1 physician-preferred TMS treatment for patients with MDD, and there are over 800 NeuroStar systems in 49 states.
With over 300 million covered lives, NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.
NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05). The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head. Long term durability of effect has not been established in a randomized controlled trial.